Downregulation of adipose LPL by PAR2 contributes to the development of hypertriglyceridemia
JCI Insight · 2024
DOI: 10.1172/jci.insight.173240 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Yiheng Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Lipoprotein Lipase, Hypertriglyceridemia, Down-Regulation, Receptor, PAR-2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Canadian Institutes of Health Research, National Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Lipoprotein lipase (LPL) hydrolyzes circulating triglycerides (TGs), releasing fatty acids (FA) and promoting lipid storage in white adipose tissue (WAT). However, the mechanisms regulating adipose LPL and its relationship with the development of hypertriglyceridemia are largely unknown. WAT from obese humans exhibited high PAR2 expression, which was inversely correlated with the LPL gene. Decreased LPL expression was also inversely correlated with elevated plasma TG levels, suggesting that adipose PAR2 might regulate hypertriglyceridemia by downregulating LPL. In mice, aging and high palmitic acid diet (PD) increased PAR2 expression in WAT, which was associated with a high level of macrophage migration inhibitory factor (MIF). MIF downregulated LPL expression and activity in adipocytes by binding with CXCR2/4 receptors and inhibiting Akt phosphorylation. In a MIF overexpression model, high-circulating MIF levels suppressed adipose LPL, and this suppression was associated with increased plasma TGs but not FA. Following PD feeding, adipose LPL expression and activity were significantly reduced, and this reduction was reversed in Par2 –/– mice. Recombinant MIF infusion restored high plasma MIF levels in Par2 –/– mice, and the levels decreased LPL and attenuated adipocyte lipid storage, leading to hypertriglyceridemia. These data collectively suggest that downregulation of adipose LPL by PAR2/MIF may contribute to the development of hypertriglyceridemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
- College of Life and Environment Sciences, Wenzhou University, Wenzhou, Zhejiang, China.
- Institute of Cardiovascular Disease, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
- Beijing Anding Hospital, Capital Medical University, Beijing, China.
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Biochemistry, Faculty of Science, and.
Förderung
- NCATS NIH HHS
- Canadian Institutes of Health Research
- National Sciences and Engineering Research Council of Canada
- National Institutes of Health
Zitieren
APA
Huang, Y., Chen, L., Li, L., Qi, Y., Tong, H., Wu, H., Xu, J., Leng, L., Cheema, S., Sun, G., Xia, Z., McGuire, J., Rodrigues, B., Young, L. H., Bucala, R., & Qi, D. (2024). Downregulation of adipose LPL by PAR2 contributes to the development of hypertriglyceridemia. JCI Insight. https://doi.org/10.1172/jci.insight.173240
Vancouver
Huang Y, Chen L, Li L, Qi Y, Tong H, Wu H, et al. Downregulation of adipose LPL by PAR2 contributes to the development of hypertriglyceridemia. JCI Insight. 2024. doi:10.1172/jci.insight.173240
BibTeX
@article{Huang2024,
author = {Huang, Yiheng and Chen, Liujun and Li, Lisha and Qi, Yadan and Tong, Haibin and Wu, Hong and Xu, Jinjie and Leng, Lin and Cheema, Sukhinder and Sun, Guang and Xia, Zhengyuan and McGuire, John and Rodrigues, Brian and Young, Lawrence H and Bucala, Richard and Qi, Dake},
title = {Downregulation of adipose LPL by PAR2 contributes to the development of hypertriglyceridemia},
journal = {JCI Insight},
year = {2024},
doi = {10.1172/jci.insight.173240}
}
EUVIMED